Human Peripheral Myelin Protein 22 messenger RNA (hPMP22 mRNA) (hPMP22 mRNA)

Human Peripheral Myelin Protein 22 (hPMP22) mRNA is the transcript of the PMP22 gene, which encodes a 22 kDa transmembrane glycoprotein primarily expressed by Schwann cells in the peripheral nervous system (UniProt P48666). This mRNA is essential for the development and maintenance of compact myelin, which facilitates rapid nerve impulse conduction (Suter & Snipes, 1995). In Charcot-Marie-Tooth disease type 1A (CMT1A), a duplication of the PMP22 gene leads to an overabundance of hPMP22 mRNA, resulting in toxic protein levels that disrupt myelin structure and cause progressive muscle weakness (Lupski et al., 1991; Hanemann et al., 1994). Conversely, a deletion of the gene leads to Hereditary Neuropathy with liability to Pressure Palsies (HNPP), highlighting the critical nature of precise mRNA dosage. Therapeutic strategies targeting hPMP22 mRNA, such as antisense oligonucleotides (ASOs) like DT-201, aim to reduce its levels to restore normal protein dosage and alleviate the CMT1A phenotype (Zhao et al., 2018; Novartis, 2023). These RNA-targeted therapies utilize mechanisms like RNase H-mediated degradation to selectively lower the transcript count in Schwann cells. Monitoring efficacy often involves measuring mRNA levels in skin biopsies or assessing nerve conduction velocity in patients. The primary challenge in targeting this molecule is achieving a therapeutic window that avoids excessive knockdown, which could inadvertently trigger HNPP-like symptoms.

Other names

PMP22 transcriptPeripheral myelin protein 22 mRNAGAS-3 mRNAGrowth arrest-specific protein 3 mRNA

RNase H-mediated mRNA degradation and RNA interference (RNAi) to reduce PMP22 protein expression levels.